Volume 39, issue 2, February 2021
9 articles in this issue
-
-
-
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
Authors
-
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Authors (first, second and last of 14)
-
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
Authors (first, second and last of 13)
-
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review
Authors (first, second and last of 8)
-
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer
Authors (first, second and last of 5)
-
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
Authors (first, second and last of 4)
-
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs
Authors (first, second and last of 4)
